Bioreactors Market Share

North America Market Forecast

By the end of 2037, North America bioreactors market is expected to capture around 37.7% share. The strong presence of biopharma companies and research organizations, and increasing investments by governments for the production of advanced therapeutic solutions are fuelling the sales of bioreactors.

In the U.S., the government’s supportive initiatives such as the National Biotechnology and Biomanufacturing Initiative to accelerate the biotechnology market growth are directly augmenting the sales of bioreactors. The supportive regulatory frameworks and funding to encourage research and production of biopharmaceuticals are boosting the demand for bioreactors. For instance, in December 2022, the U.S. Department of Energy invested USD 120 million in biotechnology and biomanufacturing innovations. Such investments further drive the adoption of bioreactors to carry out complex chemical reactions.

In Canada, the strong presence of research organizations such as the National Research Council Canada, CellCAN, and the Canadian Research Association that focuses on the production of regenerative medicines and cell therapies is contributing to the sales of bioreactors. High-performance bioreactors are essential in managing the high capacities of vaccine and drug manufacturing. Thus, the presence of advanced research organizations is creating lucrative opportunities for bioreactor manufacturers to earn high profits.

Asia Pacific Market Statistics

The Asia Pacific bioreactors market is calculated to expand at the fastest pace from 2025 to 2037. The rising biopharma product manufacturing, the growing need to improve healthcare infrastructure, and the increasing prevalence of chronic disorders are boosting the sales of advanced bioreactors. India, China, Japan, and South Korea are some of the high-growth marketplaces for bioreactors market.

In India, the increasing investments in expanding biopharma manufacturing and innovations in medical research and development sectors are pushing the sales of bioreactors. India has played a vital role during the COVID-19 pandemic by developing and exporting high volumes of vaccines across the world.  According to the India Brand Equity Foundation, the National Biopharma Mission is supporting 101 projects including more than 150 organizations and 30 MSMEs. Such initiatives are driving the high adoption of automated bioreactors to carry out complex chemical reactions.

China’s rapidly expanding aging population is driving high demand for gene therapies, biologics, and biosimilars. The biopharma companies are investing heavily to accelerate the production cycles, which is increasing the adoption of high-performance bioreactors. As per the analysis by the Center for Strategic and International Studies, China is pitching to become a biotechnology powerhouse and in the past few years, it has invested over USD 100 billion in life sciences research and development. Such huge investment moves by the country are pushing a high demand for bioreactors.